GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » 6-1 Month Momentum %

CNSP (CNS Pharmaceuticals) 6-1 Month Momentum % : -55.71% (As of Apr. 10, 2025)


View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-10), CNS Pharmaceuticals's 6-1 Month Momentum % is -55.71%.

The industry rank for CNS Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

CNSP's 6-1 Month Momentum % is ranked worse than
88.9% of 1469 companies
in the Biotechnology industry
Industry Median: -12.42 vs CNSP: -55.71

Competitive Comparison of CNS Pharmaceuticals's 6-1 Month Momentum %

For the Biotechnology subindustry, CNS Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNS Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's 6-1 Month Momentum % falls into.


;
;

CNS Pharmaceuticals  (NAS:CNSP) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNS Pharmaceuticals  (NAS:CNSP) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


CNS Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


CNS Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Executives
Christopher Downs officer: Chief Financial Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco director, officer: Chief Executive Officer PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes director 13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027